CARM1 and Miyoshi myopathy: Our findings reveal a striking dependency in MM on both CARM1 targeting and CRBN-mediated IKZF3 protein degradation, as simultaneous blockade of both pathways leads to robust MM cell killing with substantially greater potency than CARM1 inhibition or IMiD treatment alone.